Pcv51 - Cost Analysis of Safety Outcomes of Dabigatran vs. Warfarin in the Spanish National Health Service

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.598
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Dabigatran Compared With Rivaroxaban vs Warfarin

JAMA Internal Medicine
Internal Medicine
2017English

Cost of the National Health Service

The Lancet
Medicine
1954English

Efficacy and Safety of Dabigatran Versus Warfarin From the RE-LY Trial

Open Heart
Cardiovascular MedicineCardiology
2018English

The Cost-Effectiveness of Apixaban Compared to Warfarin, Aspirin, Rivaroxaban and Dabigatran in Ireland

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Pdb73 - Indirect Cost-Effectiveness Analysis of Empagliflozin Compared to Canagliflozin for Patients With T2dm and Cardiovascular Disease in the Spanish National Health Service

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcv70 - Effect of Time in Therapeutic Range on Cost and Clinical Outcomes of Atrial Fibrilation Patients : A Cost-Consequences Analysis of Rivaroxaban vs Warfarin for Turkey

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Comparative Effectiveness and Safety of Warfarin and Dabigatran in Patients With Non-Valvular Atrial Fibrillation in Japan: A Claims Database Analysis

Journal of Cardiology
Cardiovascular MedicineCardiology
2019English

An Analysis of National Collaboration With Spanish Researchers Abroad in the Health Sciences

Health Research Policy and Systems
MedicineHealth Policy
2015English

Implementing a National Strategy for Patient Safety: Lessons From the National Health Service in England

Quality and Safety in Health Care
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy